| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/29/2013 | US8362003 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
| 01/29/2013 | US8362002 Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| 01/29/2013 | US8362001 Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| 01/29/2013 | US8362000 Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| 01/29/2013 | US8361999 Methods of treating cholesterol gallstone disease with ezetimibe |
| 01/29/2013 | US8361998 Compounds and their use as IKACh blockers |
| 01/29/2013 | US8361997 Process for preparing a crystalline form of halobetasol propionate |
| 01/29/2013 | US8361996 Imidazolyl substituted steroidal and indan-1-one derivatives |
| 01/29/2013 | US8361995 Drug comprising at least one gestagen |
| 01/29/2013 | US8361994 Primary amine diazeniumdiolate heterocyclic derivatives |
| 01/29/2013 | US8361993 Hydroxy-bisphosphonic acid derivatives as vector targeting bone tissue |
| 01/29/2013 | US8361992 Complexes of 4-hydroperoxy ifosfamide as anti-tumor agents |
| 01/29/2013 | US8361990 Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods |
| 01/29/2013 | US8361989 Supporting activities of daily living |
| 01/29/2013 | US8361988 Nucleoside and nucleotide analogues with quaternary carbon centers and methods of use |
| 01/29/2013 | US8361987 DNA vaccines encoding heat shock proteins |
| 01/29/2013 | US8361984 Small interfering RNAs and methods for prevention, inhibition and/or treatment of malignant progression of breast cancer |
| 01/29/2013 | US8361982 Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell |
| 01/29/2013 | US8361981 Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| 01/29/2013 | US8361977 Compositions and methods for modulation of SMN2 splicing |
| 01/29/2013 | US8361975 Compounds and methods for treatment of sickle cell or complications associated therewith |
| 01/29/2013 | US8361974 Administration of avermectin/milbemycin compounds for the treatment of ophthalmic pathologies |
| 01/29/2013 | US8361973 Glycoside compounds and pharmaceutical compositions thereof |
| 01/29/2013 | US8361972 Pharmaceutical formulations containing an SGLT2 inhibitor |
| 01/29/2013 | US8361962 Tricyclic inhibitors of JAK |
| 01/29/2013 | US8361959 Spiro-imidazolone derivatives as glucagon receptor antagonists |
| 01/29/2013 | US8361795 Hepatopoietin and use thereof |
| 01/29/2013 | US8361787 Method for expression of small RNA molecules within a cell |
| 01/29/2013 | US8361721 Methods for detecting, diagnosing and treating human renal cell carcinoma |
| 01/29/2013 | US8361512 Nutrient compositions and methods for enhanced effectiveness of the immune system |
| 01/29/2013 | US8361500 Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom |
| 01/29/2013 | US8361499 Controlled release hydrocodone formulations |
| 01/29/2013 | US8361496 Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
| 01/29/2013 | US8361491 Mesoporous implants for administering substances and methods of producing implants |
| 01/29/2013 | US8361488 Methods and compositions for controlled release oral dosage of a vitamin D compound |
| 01/29/2013 | US8361467 Antagonist is selected from an antioxidant or an inhibitor of a pro-inflammatory interleukin, TNF- alpha synthesis, membrane-bound TNF- alpha, a natural receptor of TNF- alpha, nitric oxide synthase, phospholipase A2, apoptosis, matrix metalloproteases, or p38 kinase |
| 01/29/2013 | US8361466 Tweak receptor |
| 01/29/2013 | US8361455 Non-lithotripsic kidney-stone therapy |
| 01/29/2013 | US8361454 PVA particle for temporary embolic material and production process thereof, and temporary embolic material |
| 01/29/2013 | US8361453 Iodinated polymers |
| 01/29/2013 | US8361452 For oral administration, comprising polyethylene glycol, dibasic sodium phosphate; and, optionally, monobasic sodium phosphate; taken dissolved in water, for pre-surgery, constipation; improved patient compliance |
| 01/29/2013 | US8361444 Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections |
| 01/29/2013 | US8361442 Oxime conjugates and methods for their formation and use |
| 01/29/2013 | US8361056 System with a reservoir for perfusion management |
| 01/29/2013 | US8361014 Telescoping perfusion management system |
| 01/29/2013 | US8361013 Telescoping perfusion management system |
| 01/29/2013 | CA2731378C Therapeutic or prophylactic agent for diabetes, obesity, dyslipidemia or metabolic syndrome, comprising benzylamine derivative or pharmaceutically acceptable acid addition salt thereof |
| 01/29/2013 | CA2705481C Cephalomannine derivatives, their preparation, pharmaceutical composition and use thereof |
| 01/29/2013 | CA2694835C Novel crystalline form |
| 01/29/2013 | CA2694410C Pyridinoylpiperidines as 5-ht1f agonists |
| 01/29/2013 | CA2677781C Nitrilases |
| 01/29/2013 | CA2672860C Inhibitors of poly(adp-ribose)polymerase |
| 01/29/2013 | CA2668245C Improved laxative composition and method |
| 01/29/2013 | CA2658190C Di-amino-substituted heterocyclic compounds and methods of use |
| 01/29/2013 | CA2640409C Composition for inhibiting adhesion |
| 01/29/2013 | CA2586807C Topical nepafenac formulations |
| 01/29/2013 | CA2584179C N,n'-diphenylurea derivatives which are suitable as kinase inhibitors |
| 01/29/2013 | CA2583918C Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 01/29/2013 | CA2583457C Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation |
| 01/29/2013 | CA2582174C 4-hydroxy tamoxifen gel formulations |
| 01/29/2013 | CA2570673C Compounds and methods for treating dyslipidemia |
| 01/29/2013 | CA2569459C Glucagon receptor antagonists, preparation and therapeutic uses |
| 01/29/2013 | CA2563556C Use of ciclesonide for the treatment of respiratory diseases in a smoking patient |
| 01/29/2013 | CA2544492C Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties |
| 01/29/2013 | CA2541425C Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
| 01/29/2013 | CA2536553C Substituted 8-heteroaryl xanthines |
| 01/29/2013 | CA2528360C Anesthetic composition for topical administration comprising lidocaine, prilocaine and tetracaine |
| 01/29/2013 | CA2525946C Composition comprising a pde4 inhibitor and a pde5 inhibitor |
| 01/29/2013 | CA2507987C A vegetable composition having blood enhancing properties |
| 01/29/2013 | CA2460000C Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| 01/29/2013 | CA2459822C Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents |
| 01/29/2013 | CA2454050C Pharmaceutical formulae for thyroid hormones and procedures for obtaining them |
| 01/29/2013 | CA2448665C Sustained-release analgesic compounds |
| 01/29/2013 | CA2431891C Mutations in neuronal gene sodium-channel alpha 1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 01/29/2013 | CA2416137C Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| 01/29/2013 | CA2343929C Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| 01/29/2013 | CA2309652C Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| 01/29/2013 | CA2258485C Ribonuclease resistant rna preparation and utilization |
| 01/25/2013 | DE202007019476U1 Nicht-mucoadhäsive Filmdosisformen Non-mucoadhesive film dosage forms |
| 01/24/2013 | WO2013013240A2 Macrocyclic compounds and related compositons and methods of use |
| 01/24/2013 | WO2013013238A2 Compounds and related compositions and methods of use |
| 01/24/2013 | WO2013013228A1 Methods for determining patient response to anti-platelet aggregation therapy |
| 01/24/2013 | WO2013013211A1 Fatty acid compositions |
| 01/24/2013 | WO2013013195A1 Compositions and methods for treating polycythemia vera and essential thrombocythemia |
| 01/24/2013 | WO2013013190A1 Targeting gli proteins in human cancer by small molecules |
| 01/24/2013 | WO2013013188A1 Heterocyclic protein kinase inhibitors |
| 01/24/2013 | WO2013013178A1 Sesquiterpenes for antifungal applications |
| 01/24/2013 | WO2013013172A1 Intravaginal devices for drug delivery |
| 01/24/2013 | WO2013013143A1 Fixed dose combination of bimatoprost and brimonidine |
| 01/24/2013 | WO2013013114A1 Bioavailable compositions of amorphous piperidinyl compounds |
| 01/24/2013 | WO2013013076A1 Methods of treating pain |
| 01/24/2013 | WO2013013061A1 Methods and compounds for treating cancer |
| 01/24/2013 | WO2013013060A1 Agomelatine derivatives |
| 01/24/2013 | WO2013013055A1 System for drug delivery and monitoring |
| 01/24/2013 | WO2013013052A1 Substituted xanthine derivatives |
| 01/24/2013 | WO2013013038A2 Doping agents and polymeric compositions thereof for controlled drug delivery |
| 01/24/2013 | WO2013013031A1 Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase |
| 01/24/2013 | WO2013012997A1 Targeted osmotic lysis of cancer cells |
| 01/24/2013 | WO2013012995A1 Process for the synthesis of n-substituted cyclic alkylene ureas |
| 01/24/2013 | WO2013012991A1 Process for the synthesis of cyclic alkylene ureas |